Sionna Therapeutics (NASDAQ:SION) Stock Rating Upgraded by Wedbush

Sionna Therapeutics (NASDAQ:SION) was upgraded by investment analysts at Wedbush to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other analysts have also issued reports about the stock. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. BTIG Research restated a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, April 27th. JonesTrading upped their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Guggenheim upped their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Citigroup assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set an “outperform” rating for the company. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $53.00.

Sionna Therapeutics Stock Up 1.3%

NASDAQ SION opened at $40.97 on Monday. The company has a 50-day simple moving average of $38.29 and a two-hundred day simple moving average of $39.20. Sionna Therapeutics has a 12-month low of $11.77 and a 12-month high of $46.46. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -21.01 and a beta of 1.35.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.15. Equities analysts expect that Sionna Therapeutics will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 235,863 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. This trade represents a 6.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,131,856 shares of company stock valued at $50,834,773. Insiders own 3.90% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new position in Sionna Therapeutics in the fourth quarter worth about $36,000. Russell Investments Group Ltd. bought a new position in Sionna Therapeutics in the third quarter worth about $30,000. Balyasny Asset Management L.P. bought a new position in Sionna Therapeutics in the fourth quarter worth about $58,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics in the second quarter worth about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Sionna Therapeutics in the fourth quarter worth about $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.